Cargando…

Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation

Pancreatic ductal adenocarcinoma (PDAC) is presently one of the cancers with the worst survival rates. The current treatment options for PDAC are relatively scarce due to insufficient understanding of molecular characteristics and subtypes of PDAC. Based on next-generation sequencing (NGS), we first...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Fan, Lu, Le, Tan, Yuan, Duan, Qianqian, Lu, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521337/
https://www.ncbi.nlm.nih.gov/pubmed/34671564
http://dx.doi.org/10.3389/fonc.2021.757965
_version_ 1784584879556526080
author Meng, Fan
Lu, Le
Tan, Yuan
Duan, Qianqian
Lu, Hongwei
author_facet Meng, Fan
Lu, Le
Tan, Yuan
Duan, Qianqian
Lu, Hongwei
author_sort Meng, Fan
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is presently one of the cancers with the worst survival rates. The current treatment options for PDAC are relatively scarce due to insufficient understanding of molecular characteristics and subtypes of PDAC. Based on next-generation sequencing (NGS), we firstly presented a case about a KRAS wild-type pancreatic ductal adenocarcinoma patient harboring a concurrent targetable rare somatic novel KANK1-ALK, UPP2-NTRK3 fusion, and pathogenetic germline BRCA mutation. These two novel fusion statuses were assayed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Our findings demonstrated that comprehensive and systematic screening of PDAC for actionable genomic alteration may substantially improve the therapeutic prospects for a sizeable fraction of patients with PDAC. To improve the management of PDAC in an era of precision medicine, it is important to identify ALK or NTRK fusion-positive and pathogenic germline mutation subsets of patients who can benefit from targeted therapies.
format Online
Article
Text
id pubmed-8521337
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85213372021-10-19 Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation Meng, Fan Lu, Le Tan, Yuan Duan, Qianqian Lu, Hongwei Front Oncol Oncology Pancreatic ductal adenocarcinoma (PDAC) is presently one of the cancers with the worst survival rates. The current treatment options for PDAC are relatively scarce due to insufficient understanding of molecular characteristics and subtypes of PDAC. Based on next-generation sequencing (NGS), we firstly presented a case about a KRAS wild-type pancreatic ductal adenocarcinoma patient harboring a concurrent targetable rare somatic novel KANK1-ALK, UPP2-NTRK3 fusion, and pathogenetic germline BRCA mutation. These two novel fusion statuses were assayed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Our findings demonstrated that comprehensive and systematic screening of PDAC for actionable genomic alteration may substantially improve the therapeutic prospects for a sizeable fraction of patients with PDAC. To improve the management of PDAC in an era of precision medicine, it is important to identify ALK or NTRK fusion-positive and pathogenic germline mutation subsets of patients who can benefit from targeted therapies. Frontiers Media S.A. 2021-10-04 /pmc/articles/PMC8521337/ /pubmed/34671564 http://dx.doi.org/10.3389/fonc.2021.757965 Text en Copyright © 2021 Meng, Lu, Tan, Duan and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Meng, Fan
Lu, Le
Tan, Yuan
Duan, Qianqian
Lu, Hongwei
Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
title Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
title_full Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
title_fullStr Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
title_full_unstemmed Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
title_short Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
title_sort case report: a pancreatic ductal adenocarcinoma patient with concurrent targetable somatic novel kank1-alk, upp2-ntrk3 fusion, and pathogenetic germline brca mutation
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521337/
https://www.ncbi.nlm.nih.gov/pubmed/34671564
http://dx.doi.org/10.3389/fonc.2021.757965
work_keys_str_mv AT mengfan casereportapancreaticductaladenocarcinomapatientwithconcurrenttargetablesomaticnovelkank1alkupp2ntrk3fusionandpathogeneticgermlinebrcamutation
AT lule casereportapancreaticductaladenocarcinomapatientwithconcurrenttargetablesomaticnovelkank1alkupp2ntrk3fusionandpathogeneticgermlinebrcamutation
AT tanyuan casereportapancreaticductaladenocarcinomapatientwithconcurrenttargetablesomaticnovelkank1alkupp2ntrk3fusionandpathogeneticgermlinebrcamutation
AT duanqianqian casereportapancreaticductaladenocarcinomapatientwithconcurrenttargetablesomaticnovelkank1alkupp2ntrk3fusionandpathogeneticgermlinebrcamutation
AT luhongwei casereportapancreaticductaladenocarcinomapatientwithconcurrenttargetablesomaticnovelkank1alkupp2ntrk3fusionandpathogeneticgermlinebrcamutation